Kane Biotech Inc.

Equities

KNE

CA4838092084

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:56:26 2024-04-18 pm EDT			5-day change	1st Jan Change
0.13 ^CAD	+4.00%		-7.14%	+62.50%

Apr. 15	Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	MT
Apr. 15	Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	CI

Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 27, 2021 at 04:10 pm EDT

Kane Biotech Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was CAD 376,039 compared to CAD 456,139 a year ago. Operating loss was CAD 983,735 compared to CAD 1.444 million a year ago. Net loss was CAD 908,467 compared to CAD 1.363 million a year ago.

Latest news about Kane Biotech Inc.

Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	Apr. 15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11	MT
Transcript : Kane Biotech Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	Mar. 26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20	MT
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair	Feb. 22	CI
Transcript : Kane Biotech Inc. - Shareholder/Analyst Call	Feb. 20
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31	CI
Kane Biotech Announces Correction to Press Release	Dec. 29	MT
Kane Biotech Inc. Announces Amendment to Its Credit Facility	Dec. 28	CI
Kane Biotech Gains 6% As Says To Sell Interest In STEM Animal Health	Dec. 20	MT
Kane Biotech To Sell Interest In STEM Animal Health	Dec. 20	MT
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
Transcript : Kane Biotech Inc., Q3 2023 Earnings Call, Nov 28, 2023	Nov. 28
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	Nov. 28	MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022	Nov. 28	MT
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Kane Biotech Inc. Appoints John Coleman to the Board of Directors	Nov. 16	CI
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum	Nov. 02	CI
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum	23-10-25	MT
Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum	23-10-25	CI

Chart Kane Biotech Inc.

Duration

Period

More charts

Company Profile

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

Sector

Biotechnology & Medical Research

Calendar

04:15pm - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KANE BIOTECH INC.	+62.50%	11.94M
IQVIA HOLDINGS INC.	-1.82%	41.36B
LONZA GROUP AG	+44.25%	41.3B
MODERNA, INC.	+2.56%	39.61B
CELLTRION, INC.	-12.11%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.38B
MEDPACE HOLDINGS, INC.	+22.12%	11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.82B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.07B

Other Biotechnology & Medical Research